Find a Doctor
Robert Yoo, DO, is the director of the Brain Metastasis Program at Barrow Neurological Institute and an assistant professor in medical oncology. He is board certified in both medical oncology and hematology by the American Osteopathic Board of Internal Medicine.
Dr. Yoo’s expertise includes caring for patients with advanced cancers that are metastasized to the brain or spine and head and neck cancers. With his hematology background, Dr. Yoo also treats various blood cancer types involving the brain and spine, such as lymphoma and multiple myeloma. He is a member of the American Osteopathic Association, the American Society of Clinical Oncology, the American Society of Hematology, and the Society for Neuro-Oncology.
Dr. Yoo earned his medical degree from the Michigan State University College of Osteopathic Medicine in East Lansing. He completed his internal medicine residency at Beaumont Hospital in Farmington Hills, the primary teaching hospital of Michigan State University. He also completed a fellowship in hematology and oncology at the Barbara Ann Karmanos Cancer Institute, an affiliate of the Wayne State University School of Medicine in Detroit.
Dr. Yoo has a longstanding interest in genomics and tumors with unique molecular biology. He believes that a better understanding of tumor biology can help overcome treatment resistance to provide precision-based treatments for brain tumors. Dr. Yoo emphasizes comprehensive, state-of-the-art patient care with treatment options such as immunotherapy, targeted therapy agents, and cancer vaccines.
- Aetna
- AHCCS (Referral Required)
- Blue Cross Blue Shield
- Blue Cross Blue Shield Third Party
- Cigna
- Commercial Networks
- Government Plans
- Humana
- Market Place Plans (Referral Required)
- Medicare Advantage Plans (Referral Required)
- United Healthcare
- Fellowship, Chief Fellow, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Hematology/Oncology, 2015-2018.
- Residency, Beaumont Hospital, Michigan State University, Internal Medicine, 2012-2015
- DO, Michigan State University College of Osteopathic Medicine, 2012
- BS, Michigan State University, Human Biology, 2007
- American Osteopathic Association
- American Society of Clinical Oncology
- American Society of Hematology
- Society for Neuro-Oncology
- 40-Under-40 Business Leadership Award, Phoenix Business Journal, 2020
Hemophagocytic lymphohistiocytosis (HLH): Elusive diagnosis of disseminated
Date: 09/2017
Authors: Eloy E Ordaya, Sulieman Abu Jarir, Robert Yoo, Pranatharthi H Chandrasekar
- English
- (602) 406-6387
- Fax: (602) 406-2931
Robert Yoo, DO, is the director of the Brain Metastasis Program at Barrow Neurological Institute and an assistant professor in medical oncology. He is board certified in both medical oncology and hematology by the American Osteopathic Board of Internal Medicine.
Dr. Yoo’s expertise includes caring for patients with advanced cancers that are metastasized to the brain or spine and head and neck cancers. With his hematology background, Dr. Yoo also treats various blood cancer types involving the brain and spine, such as lymphoma and multiple myeloma. He is a member of the American Osteopathic Association, the American Society of Clinical Oncology, the American Society of Hematology, and the Society for Neuro-Oncology.
Dr. Yoo earned his medical degree from the Michigan State University College of Osteopathic Medicine in East Lansing. He completed his internal medicine residency at Beaumont Hospital in Farmington Hills, the primary teaching hospital of Michigan State University. He also completed a fellowship in hematology and oncology at the Barbara Ann Karmanos Cancer Institute, an affiliate of the Wayne State University School of Medicine in Detroit.
Dr. Yoo has a longstanding interest in genomics and tumors with unique molecular biology. He believes that a better understanding of tumor biology can help overcome treatment resistance to provide precision-based treatments for brain tumors. Dr. Yoo emphasizes comprehensive, state-of-the-art patient care with treatment options such as immunotherapy, targeted therapy agents, and cancer vaccines.
- (602) 406-6387
- Fax: (602) 406-2931
- Aetna
- AHCCS (Referral Required)
- Blue Cross Blue Shield
- Blue Cross Blue Shield Third Party
- Cigna
- Commercial Networks
- Government Plans
- Humana
- Market Place Plans (Referral Required)
- Medicare Advantage Plans (Referral Required)
- United Healthcare
- Fellowship, Chief Fellow, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Hematology/Oncology, 2015-2018.
- Residency, Beaumont Hospital, Michigan State University, Internal Medicine, 2012-2015
- DO, Michigan State University College of Osteopathic Medicine, 2012
- BS, Michigan State University, Human Biology, 2007
- American Osteopathic Association
- American Society of Clinical Oncology
- American Society of Hematology
- Society for Neuro-Oncology
- 40-Under-40 Business Leadership Award, Phoenix Business Journal, 2020
Hemophagocytic lymphohistiocytosis (HLH): Elusive diagnosis of disseminated
Date: 09/2017
Authors: Eloy E Ordaya, Sulieman Abu Jarir, Robert Yoo, Pranatharthi H Chandrasekar
- English